
Mayo Clinic AI Spots Pancreatic Cancer 3 Years Early
REDMOD, Mayo Clinic's radiomics AI, detects 73% of pancreatic cancers in CT scans that look normal to radiologists - nearly double the rate specialists achieve.
They summarize our coverage. We write it.
Newsletters like this one rebroadcast our headlines - often without the full review, the source reading, or the analysis underneath. Our weekly briefing sends the work they paraphrase, straight from the desk, before they get to it.
Free, weekly, no spam. One email every Tuesday. Unsubscribe anytime.

REDMOD, Mayo Clinic's radiomics AI, detects 73% of pancreatic cancers in CT scans that look normal to radiologists - nearly double the rate specialists achieve.

Five leading AI drug discovery platforms compared - AlphaFold 3, IsoDDE, Recursion OS, Insilico Pharma.AI, and NVIDIA BioNeMo. Access, capabilities, pricing, and clinical results.

Seth Showes' viral blog post describes sequencing his whole genome on an Oxford Nanopore MinION in his kitchen over 72 hours, with Claude generating the BED file that targeted his autoimmune-risk genes. The kit costs $3,200. The AI's role is more interesting than either number.

OpenAI's first domain-specific reasoning model for biology and drug discovery, launched April 16 2026 as a US-only research preview with a 0.751 BixBench score.

OpenAI launched GPT-Rosalind on April 16, a frontier reasoning model for drug discovery that outranked human experts on RNA prediction and competes directly with Google DeepMind's AlphaFold.

Novo Nordisk signs a sweeping AI partnership with OpenAI covering drug discovery, manufacturing, and supply chain - but the governance details are thin.

Anthropic acquires Coefficient Bio, an eight-month-old stealth startup with fewer than ten employees, in a $400M all-stock deal to push into pharmaceutical AI.

Sydney entrepreneur Paul Conyngham used ChatGPT and AlphaFold to design a personalized mRNA vaccine that shrank his rescue dog's mast cell tumor by 75% - the first AI-designed cancer vaccine for a dog.

Arc Institute and NVIDIA release Evo 2, a 40B-parameter open-source AI trained on 9.3 trillion nucleotides from every domain of life, with full weights, code, and training data.

Google DeepMind's drug discovery spin-off releases a proprietary AI engine that doubles AlphaFold 3's accuracy but breaks with the open-science tradition that made its predecessor a Nobel Prize winner.